Company Overview - PACS Group, Inc. is a leading post-acute care provider operating 316 facilities across 17 states, with over 32,000 skilled nursing beds and 2,400 assisted living beds, focusing on quality care [2] - The company has expanded rapidly since Q2 2024, adding 96 facilities to its portfolio [2] Financial Performance - As of June 30, PACS reported an occupancy rate of 88.9%, significantly higher than the industry average of 78% [3] - The company has cash reserves of $294.2 million, nearly double the levels at the end of 2024 [3] - Management projects record revenue and adjusted EBITDA for the first half of 2025 once financial filings are complete [3] Regulatory and Governance Issues - The New York Stock Exchange extended PACS's trading period to November 19, 2025, allowing more time for the company to complete financial restatements and SEC filings [3] - PACS is cooperating with an independent Audit Committee investigation into past financial matters [3] - Leadership changes occurred with the resignation of CFO Derick Apt after an internal policy investigation, and a former CFO has been appointed as interim [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving PACS Group, Inc. and its officers or directors [1] Group 1: Company Developments - On September 8, 2025, PACS announced the resignation of Chief Financial Officer Derick Apt due to allegations of accepting high-value items from associated individuals, which violated company policies [3] - Following the announcement of the CFO's resignation, PACS's stock price dropped by $3.29 per share, a decline of 29.08%, closing at $8.03 per share on September 9, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving PACS Group, Inc. and its officers or directors [1]. Group 1: Company Developments - On September 8, 2025, PACS announced the resignation of Chief Financial Officer Derick Apt due to allegations of accepting high-value items from associated individuals, which violated company policies [2]. - Following the announcement of the CFO's resignation, PACS's stock price dropped by $3.29 per share, representing a decline of 29.08%, closing at $8.03 per share on September 9, 2025 [2]. Group 2: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].

Group 1 - PACS Group, Inc. shares increased by 24.5% to $9.6, following a significant trading volume, contrasting with a 32.8% loss over the past four weeks [1][2] - The price surge was driven by investor optimism due to the announcement of four preliminary key operating metrics expected for the six months ending June 30, 2025, indicating solid business momentum [2] - The company anticipates quarterly earnings of $0.47 per share, reflecting a year-over-year increase of 771.4%, with revenues projected at $1.11 billion, up 12.8% from the previous year [3] Group 2 - The consensus EPS estimate for PACS has remained unchanged over the last 30 days, suggesting that stock price increases may not sustain without earnings estimate revisions [4] - PACS Group, Inc. holds a Zacks Rank of 3 (Hold), indicating a neutral outlook within the Zacks Medical Services industry [4] - Cencora, another company in the same industry, has a consensus EPS estimate of $3.84, representing a 15% increase from the previous year, and also holds a Zacks Rank of 3 (Hold) [5]

[FORM 8-K Filing Details](index=1&type=section&id=FORM%208-K%20Filing%20Details) This section details the Form 8-K filing, covering registrant information, securities registration, and general filing specifics [Registrant and Filing Information](index=1&type=section&id=Registrant%20and%20Filing%20Information) This section provides the administrative details of the Form 8-K filing, including the registrant's identity, incorporation state, address, and the report's filing date - Registrant: **PACS GROUP, INC.**, incorporated in Delaware[1](index=1&type=chunk) - Filing Date: **September 11, 2025**[1](index=1&type=chunk) - Registrant's principal executive offices: **262 N. University Ave., Farmington, Utah 84025**[1](index=1&type=chunk) [Securities Registration](index=1&type=section&id=Securities%20Registration) This part details the company's registered securities, their trading symbol, and the exchange on which they are listed, also indicating that the registrant is not an emerging growth company Securities Registration Details | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :---------------------------------------- | | Common Stock, $0.001 par value per share | PACS | The New York Stock Exchange | - The registrant is not an emerging growth company[3](index=3&type=chunk) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) This section reports the announcement of preliminary operating metrics and clarifies the filing status and associated liabilities [Announcement of Preliminary Operating Metrics](index=2&type=section&id=Announcement%20of%20Preliminary%20Operating%20Metrics) PACS Group, Inc. issued a press release on September 11, 2025, announcing select unaudited preliminary operating metrics, which is furnished as Exhibit 99.1 to this Form 8-K - On **September 11, 2025**, PACS Group, Inc. issued a press release[4](index=4&type=chunk) - The press release announced select unaudited preliminary operating metrics[4](index=4&type=chunk) - A copy of the press release is furnished as **Exhibit 99.1** to this Current Report on Form 8-K[4](index=4&type=chunk) [Filing Status and Liabilities Disclaimer](index=2&type=section&id=Filing%20Status%20and%20Liabilities%20Disclaimer) This section clarifies that the information in this Form 8-K, including Exhibit 99.1, is furnished and not considered 'filed' for Section 18 liability purposes of the Exchange Act, nor is it automatically incorporated by reference into other filings - The information in this Form 8-K (including Exhibit 99.1) shall not be deemed 'filed' for purposes of **Section 18 of the Securities Exchange Act of 1934**[5](index=5&type=chunk) - It is not subject to the liabilities of that section[5](index=5&type=chunk) - It shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference[5](index=5&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) This section lists the financial statements and exhibits included in the Form 8-K filing [Exhibits List](index=2&type=section&id=Exhibits%20List) This section provides a table listing the exhibits accompanying the Form 8-K filing, specifically the press release and the interactive data file Form 8-K Exhibits | Exhibit No. | Description | | :---------- | :---------- | | 99.1 | Press Release of the Company dated September 11, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | [SIGNATURES](index=3&type=section&id=SIGNATURES) This section formally concludes the report with the authorized signature and date [Execution of Report](index=3&type=section&id=Execution%20of%20Report) This section formally concludes the report, confirming its execution on behalf of PACS Group, Inc. by its Chief Executive Officer - The report was duly caused to be signed on behalf of **PACS GROUP, INC.**[8](index=8&type=chunk)[9](index=9&type=chunk) - Signed by **Jason Murray**, Chief Executive Officer[10](index=10&type=chunk) - Date of signature: **September 11, 2025**[10](index=10&type=chunk)

Core Points - PACS Group, Inc. has been granted an additional trading period by the NYSE until November 19, 2025, to facilitate the completion of its financial statement restatement [1] Group 1 - The NYSE Listing Operations Committee approved the extension on September 9, 2025, allowing PACS more time for its ongoing review [1] - The additional trading period is crucial for PACS to address the previously announced restatement of its financial statements [1]

Company Overview - PACS Group, Inc. shares increased by 21.8% to close at $12.35, with trading volume significantly higher than usual, contrasting with a 6.2% loss over the past four weeks [1] - The company is undergoing an audit committee investigation, which is nearly complete, and no integrity issues have been found regarding top management [2] Financial Performance - PACS Group is expected to report quarterly earnings of $0.42 per share, reflecting a year-over-year increase of 10.5%, with revenues projected at $1.09 billion, up 16.5% from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating stability in earnings expectations [4] Industry Context - PACS Group operates within the Zacks Medical Services industry, where Sotera Health Company, a peer, has seen a 3.3% decline in its stock price recently and a negative return of 11.6% over the past month [4] - Sotera Health's consensus EPS estimate has also remained unchanged, currently at $0.17, which is a decrease of 10.5% compared to the previous year [5]

Core Insights - Konica Minolta Healthcare Americas, Inc. has launched the next-generation Exa® Platform, featuring the most advanced version of Exa PACS|RIS to date, which includes a new API platform for integration with strategic partners [1] - The new Exa PACS|RIS version introduces Exa Advanced Imaging with enhanced Multi Planar Reconstruction (MPR) and full 3D image reconstruction capabilities, streamlining clinician workflows [1][4] - The Exa PAC|RIS ecosystem includes NewVue, an AI-powered radiologist worklist, Clearpath Technologies' automated record-sharing platform, and Quinsite's Comprehensive Healthcare Analytics Platform™ for data-driven decision-making [3] Company Overview - Konica Minolta Healthcare is a leading provider in medical diagnostic imaging and healthcare IT, focusing on transforming primary imaging technologies to enhance diagnostic capabilities [5] - The company has a legacy of 150 years in innovation, evolving from a camera and film manufacturer to a strategic partner in healthcare imaging solutions [6][7] - The recent launch of Exa Enterprise, an integrated PACS and Vendor Neutral Archive (VNA), complements the Exa PACS|RIS, providing comprehensive workflow and image viewing solutions across specialties [4]

Core Viewpoint - A class action lawsuit has been filed against PACS Group, Inc. for alleged violations of federal securities laws related to false statements and fraudulent activities concerning Medicare claims [1][3]. Group 1: Lawsuit Details - The lawsuit targets shareholders who purchased PACS securities during its IPO on April 11, 2024, or within the class period from April 11, 2024, to November 5, 2024 [2]. - Allegations include PACS engaging in a false Medicare claim scam that reportedly generated over 100% of its operating and net income from 2020 to 2023 [3]. - The company is accused of billing Medicare for thousands of unnecessary therapies and falsifying documentation regarding licensure and staffing [3]. Group 2: Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, aiming to enhance investor returns through effective legal advocacy [4]. - The firm represents some of the largest hedge funds and alternative asset managers, emphasizing the value of litigation claims as significant assets [4].

Core Viewpoint - A lawsuit has been filed against PACS Group, Inc. and its senior executives for potential violations of federal securities laws, alleging misconduct related to the company's financial practices and Medicare benefits access [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Manchin v. PACS Group, Inc., et al., No. 24-cv-08636 [2]. - Investors have until January 13, 2025, to request to lead the case [2]. Group 2: Allegations Against PACS - PACS is alleged to be one of the largest operators of skilled nursing facilities in the U.S., claiming to have a successful turnaround strategy to enhance profitability [3]. - The complaint asserts that PACS's turnaround was based on illicitly accessing Medicare benefits for thousands of patients [3]. - Hindenburg Research published a report alleging that PACS abused a COVID-era waiver to improperly access Medicare benefits, which significantly inflated the company's operating and net income from 2020 to 2023 [4]. Group 3: Financial Impact - Following the allegations, PACS's stock price experienced a significant decline, dropping 27.8% from $42.94 to $31.01 per share on November 4, 2024, and further declining 38.8% from $29.54 to $18.09 per share on November 6, 2024 [4].